About 8th Annual Mash Drug Development Summit 2024

The MASH field is celebrating a milestone with the FDA approval of Madrigal’s drug this March, marking the first approved MASH therapeutic. This breakthrough opens the door for a wave of promising therapeutics from companies like Eli Lilly, Boehringer Ingelheim, AstraZeneca, Amgen, and Akero Therapeutics, all progressing through phase 1, 2, and 3 clinical trials.

The 8th MASH Drug Development Summit, your one-stop-shop for the latest in MASH therapeutic innovation, will address key topics such as optimizing clinical trial design, overcoming regulatory challenges, combating fibrosis, navigating GLP-1 usage, integrating real-world evidence, and achieving accurate non-invasive biomarkers. With the MASH therapeutic landscape already experiencing significant advancements in 2024, this summit is the premier venue for the community to come together and discuss the evolving opportunities in MASH and metabolic disease drug development.